Coloplast A/S (COLO-B.CO)
- Previous Close
841.00 - Open
838.20 - Bid 850.00 x --
- Ask 853.60 x --
- Day's Range
838.20 - 856.40 - 52 Week Range
689.20 - 977.60 - Volume
237,969 - Avg. Volume
229,339 - Market Cap (intraday)
191.284B - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
37.88 - EPS (TTM)
22.44 - Earnings Date May 7, 2024
- Forward Dividend & Yield 21.00 (2.47%)
- Ex-Dividend Date May 13, 2024
- 1y Target Est
934.70
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
www.coloplast.com15,930
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: COLO-B.CO
Performance Overview: COLO-B.CO
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COLO-B.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COLO-B.CO
Valuation Measures
Market Cap
191.28B
Enterprise Value
214.90B
Trailing P/E
37.93
Forward P/E
35.09
PEG Ratio (5yr expected)
3.26
Price/Sales (ttm)
7.38
Price/Book (mrq)
11.81
Enterprise Value/Revenue
8.42
Enterprise Value/EBITDA
26.17
Financial Highlights
Profitability and Income Statement
Profit Margin
19.45%
Return on Assets (ttm)
10.51%
Return on Equity (ttm)
42.74%
Revenue (ttm)
25.53B
Net Income Avi to Common (ttm)
4.97B
Diluted EPS (ttm)
22.44
Balance Sheet and Cash Flow
Total Cash (mrq)
889M
Total Debt/Equity (mrq)
151.29%
Levered Free Cash Flow (ttm)
3.4B
Research Analysis: COLO-B.CO
Company Insights: COLO-B.CO
COLO-B.CO does not have Company Insights